Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Clinical Immunology
Published in: Journal of Clinical Immunology 3/2007

01-05-2007 | Original Paper

Intravenous Immunoglobulin: An Update on the Clinical Use and Mechanisms of Action

Authors: VIR-SINGH NEGI, SRIRAMULU ELLURU, SOPHIE SIBÉRIL, STÉPHANIE GRAFF-DUBOIS, LUC MOUTHON, MICHEL D. KAZATCHKINE, SÉBASTIEN LACROIX-DESMAZES, JAGADEESH BAYRY, SRINI V. KAVERI

Published in: Journal of Clinical Immunology | Issue 3/2007

Login to get access

Abstract

Initially used as a replacement therapy for immunodeficiency diseases, intravenous immunoglobulin (IVIg) is now widely used for a number of autoimmune and inflammatory diseases. Considerable progress has been made in understanding the mechanisms by which IVIg exerts immunomodulatory effects in autoimmune and inflammatory disorders. The mechanisms of action of IVIg are complex, involving modulation of expression and function of Fc receptors, interference with activation of complement and the cytokine network and of idiotype network, regulation of cell growth, and effects on the activation, differentiation, and effector functions of dendritic cells, and T and B cells.
Literature
1.
Kazatchkine MD, Kaveri SV: Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 345:747–755, 2001PubMed
2.
Gold R, Stangel M, Dalakas MC: Drug Insight: The use of intravenous immunoglobulin in neurology-therapeutic considerations and practical issues. Nat Clin Pract Neurol 3:36–44, 2007PubMed
3.
Dalakas MC: Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA 291:2367–2375, 2004PubMed
4.
Berland R, Wortis HH: Origins and functions of B-1 cells with notes on the role of CD5. Annu Rev Immunol 20:253–300, 2002PubMed
5.
Lacroix-Desmazes S, Kaveri SV, Mouthon L, Ayouba A, Malanchere E, Coutinho A, Kazatchkine MD: Self-reactive antibodies (natural autoantibodies) in healthy individuals. J Immunol Methods 216:117–137, 1998PubMed
6.
Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC: Predominant autoantibody production by early human B cell precursors. Science 301:1374–1377, 2003PubMed
7.
Rossi F, Kazatchkine MD: Antiidiotypes against autoantibodies in pooled normal human polyspecific Ig. J Immunol 143:4104–4109, 1989PubMed
8.
Rossi F, Dietrich G, Kazatchkine MD: Anti-idiotypes against autoantibodies in normal immunoglobulins: Evidence for network regulation of human autoimmune responses. Immunol Rev 110:135–149, 1989PubMed
9.
Marchalonis JJ, Kaymaz H, Dedeoglu F, Schluter SF, Yocum DE, Edmundson AB: Human autoantibodies reactive with synthetic autoantigens from T-cell receptor beta chain. Proc Natl Acad Sci USA 89:3325–3329, 1992PubMed
10.
Vassilev T, Gelin C, Kaveri SV, Zilber MT, Boumsell L, Kazatchkine MD: Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg). Clin Exp Immunol 92:369–372, 1993PubMedCrossRef
11.
Hurez V, Kaveri SV, Mouhoub A, Dietrich G, Mani JC, Klatzmann D, Kazatchkine MD: Anti-CD4 activity of normal human immunoglobulin G for therapeutic use. (Intravenous immunoglobulin, IVIg). Ther Immunol 1:269–277, 1994PubMed
12.
Bendtzen K, Hansen MB, Ross C, Svenson M: High-avidity autoantibodies to cytokines. Immunol Today 19:209–211, 1998PubMed
13.
Svenson M, Hansen MB, Ross C, Diamant M, Rieneck K, Nielsen H, Bendtzen K: Antibody to granulocyte-macrophage colony-stimulating factor is a dominant anti-cytokine activity in human IgG preparations. Blood 91:2054–2061, 1998PubMed
14.
Kaveri S, Vassilev T, Hurez V, Lengagne R, Lefranc C, Cot S, Pouletty P, Glotz D, Kazatchkine MD: Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use. J Clin Invest 97:865–869, 1996PubMed
15.
Prasad NK, Papoff G, Zeuner A, Bonnin E, Kazatchkine MD, Ruberti G, Kaveri SV: Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: A novel mechanism of action of IVIg involving the Fas apoptotic pathway. J Immunol 161:3781–3790, 1998PubMed
16.
Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, Hunziker T, Saurat JH, Tschopp J, French LE: Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 282:490–493, 1998PubMed
17.
Vassilev T, Kazatchkine MD, Duong Van Huyen JP, Mekrache M, Bonnin E, Korinth D, Baruch D, Mani JC, Lecroubier C, Schriever F, Kaveri SV: Inhibition of cell adhesion by antibodies to Arg-Gly-Asp (RGD) in normal immunoglobulin for therapeutic use (intravenous immunoglobulin, IVIg). Blood 93:3624–3631, 1999PubMed
18.
Bayry J, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV: Intravenous immunoglobulin for infectious diseases: Back to the pre-antibiotic and passive prophylaxis era? Trends Pharmacol Sci 25:306–310, 2004PubMed
19.
Busse PJ, Razvi S, Cunningham-Rundles C: Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency. J Allergy Clin Immunol 109:1001–1004, 2002PubMed
20.
Ochs HD, Gupta S, Kiessling P, Nicolay U, Berger M: Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol 26:265–273, 2006PubMed
21.
de Gracia J, Vendrell M, Alvarez A, Pallisa E, Rodrigo MJ, de la Rosa D, Mata F, Andreu J, Morell F: Immunoglobulin therapy to control lung damage in patients with common variable immunodeficiency. Int Immunopharmacol 4:745–753, 2004PubMed
22.
Chapel H, Geha R, Rosen F: Primary immunodeficiency diseases: An update. Clin Exp Immunol 132:9–135, 2003PubMed
23.
Eijkhout HW, van der Meer JW, Kallenberg CG, Weening RS, van Dissel JT, Sanders LA, Strengers PF, Nienhuis H, Schellekens PT: The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randomized, double-blind, multicenter crossover trial. Ann Intern Med 135:165–174, 2001PubMed
24.
Chapel H, Griffiths H, Brennan V, Bunch C, Lea J, Lee M: Hypogammaglobulinaemia in low grade B cell tumours; significance and therapy. Immunol Invest 20:187–191, 1991PubMed
25.
Chapel HM, Lee M, Hargreaves R, Pamphilon DH, Prentice AG: Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma. Lancet 343:1059–1063, 1994PubMed
26.
Molica S, Musto P, Chiurazzi F, Specchia G, Brugiatelli M, Cicoira L, Levato D, Nobile F, Carotenuto M, Liso V, Rotoli B: Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIg) in chronic lymphocytic leukemia. Results of a crossover study. Haematologica 81:121–126, 1996PubMed
27.
Olopoenia L, Young M, White D, Barnes S, Rahbar F, Fomufod A: Intravenous immunoglobulin in symptomatic and asymptomatic children with perinatal HIV infection. J Natl Med Assoc 89:543–547, 1997PubMed
28.
Sullivan KM, Kopecky KJ, Jocom J, Fisher L, Buckner CD, Meyers JD, Counts GW, Bowden RA, Peterson FB, Witherspoon RP, et al.: Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med 323:705–712, 1990PubMedCrossRef
29.
Cordonnier C, Chevret S, Legrand M, Rafi H, Dhedin N, Lehmann B, Bassompierre F, Gluckman E: Should immunoglobulin therapy be used in allogeneic stem-cell transplantation? A randomized, double-blind, dose effect, placebo-controlled, multicenter trial. Ann Intern Med 139:8–18, 2003PubMed
30.
Jolles S, Sewell WA, Misbah SA: Clinical uses of intravenous immunoglobulin. Clin Exp Immunol 142:1–11, 2005PubMed
31.
Imbach P, Barandun S, d’Apuzzo V, Baumgartner C, Hirt A, Morell A, Rossi E, Schoni M, Vest M, Wagner HP: High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1:1228–1231, 1981PubMed
32.
Fehr J, Hofmann V, Kappeler U: Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin. N Engl J Med 306:1254–1258, 1982PubMedCrossRef
33.
Bierling P, Godeau B: Intravenous immunoglobulin and autoimmune thrombocytopenic purpura: 22 years on. Vox Sang 86:8–14, 2004PubMed
34.
Bussel J: Treatment of immune thrombocytopenic purpura in adults. Semin Hematol 43:S3–S10; discussion S18–S19, 2006PubMed
35.
Tarantino M: Recent advances in the treatment of childhood immune thrombocytopenic purpura. Semin Hematol 43:S11–S17; discussion S18–S19, 2006PubMed
36.
Go RS, Johnston KL, Bruden KC: The association between platelet autoantibody specificity and response to intravenous immunoglobulin G in the treatment of patients with immune thrombocytopenia. Haematologica 92:283–284, 2007PubMed
37.
Mouthon L, Guillevin L, Tellier Z: Intravenous immunoglobulins in autoimmune- or parvovirus B19-mediated pure red-cell aplasia. Autoimmun Rev 4:264–269, 2005PubMed
38.
Bux J, Behrens G, Jaeger G, Welte K: Diagnosis and clinical course of autoimmune neutropenia in infancy: Analysis of 240 cases. Blood 91:181–186, 1998PubMed
39.
Gomard-Mennesson E, Ruivard M, Koenig M, Woods A, Magy N, Ninet J, Rousset H, Salles G, Broussolle C, Seve P: Treatment of isolated severe immune hemolytic anaemia associated with systemic lupus erythematosus: 26 cases. Lupus 15:223–231, 2006PubMed
40.
Delgado J, Jimenez-Yuste V, Hernandez-Navarro F, Villar A: Acquired haemophilia: Review and meta-analysis focused on therapy and prognostic factors. Br J Haematol 121:21–35, 2003PubMed
41.
Hughes RA, Raphael JC, Swan AV, Doorn PA: Intravenous immunoglobulin for Guillain–Barre syndrome. Cochrane Database Syst Rev CD002063, 2004
42.
Federico P, Zochodne DW, Hahn AF, Brown WF, Feasby TE: Multifocal motor neuropathy improved by IVIg: Randomized, double-blind, placebo-controlled study. Neurology 55:1256–1262, 2000PubMed
43.
van den Berg-Vos RM, Franssen H, Visser J, de Visser M, de Haan RJ, Wokke JH, van den Berg LH: Disease severity in multifocal motor neuropathy and its association with the response to immunoglobulin treatment. J Neurol 249:330–336, 2002PubMed
44.
Hughes R, Bensa S, Willison H, van den Bergh P, Comi G, Illa I, Nobile-Orazio E, van Doorn P, Dalakas M, Bojar M, Swan A: Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 50:195–201, 2001PubMed
45.
Mendell JR, Barohn RJ, Freimer ML, Kissel JT, King W, Nagaraja HN, Rice R, Campbell WW, Donofrio PD, Jackson CE, Lewis RA, Shy M, Simpson DM, Parry GJ, Rivner MH, Thornton CA, Bromberg MB, Tandan R, Harati Y, Giuliani MJ: Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 56:445–449, 2001PubMed
46.
Gajdos P, Tranchant C, Clair B, Bolgert F, Eymard B, Stojkovic T, Attarian S, Chevret S: Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: A randomized double-blind clinical trial. Arch Neurol 62:1689–1693, 2005PubMed
47.
Bain PG, Motomura M, Newsom-Davis J, Misbah SA, Chapel HM, Lee ML, Vincent A, Lang B: Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert–Eaton myasthenic syndrome. Neurology 47:678–683, 1996PubMed
48.
Dalakas MC, Fujii M, Li M, Lutfi B, Kyhos J, McElroy B: High-dose intravenous immune globulin for stiff-person syndrome. N Engl J Med 345:1870–1876, 2001PubMed
49.
Sorensen PS, Fazekas F, Lee M: Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: A meta-analysis. Eur J Neurol 9:557–563, 2002PubMed
50.
Achiron A, Kishner I, Dolev M, Stern Y, Dulitzky M, Schiff E, Achiron R: Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-related relapses in multiple sclerosis. J Neurol 251:1133–1137, 2004PubMed
51.
Hommes OR, Sorensen PS, Fazekas F, Enriquez MM, Koelmel HW, Fernandez O, Pozzilli C, O’Connor P: Intravenous immunoglobulin in secondary progressive multiple sclerosis: Randomised placebo-controlled trial. Lancet 364:1149–1156, 2004PubMed
52.
Dalakas MC: Mechanisms of disease: signaling pathways and immunobiology of inflammatory myopathies. Nat Clin Pract Rheumatol 2:219–227, 2006PubMed
53.
Toubi E, Kessel A, Shoenfeld Y: High-dose intravenous immunoglobulins: An option in the treatment of systemic lupus erythematosus. Hum Immunol 66:395–402, 2005PubMed
54.
Braun-Moscovici Y, Furst DE: Immunoglobulin for rheumatic diseases in the twenty-first century: Take it or leave it? Curr Opin Rheumatol 15:237–245, 2003PubMed
55.
Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, Dinsmore ST, McCrosky S: A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 329:1993–2000, 1993PubMed
56.
Walter MC, Lochmuller H, Toepfer M, Schlotter B, Reilich P, Schroder M, Muller-Felber W, Pongratz D: High-dose immunoglobulin therapy in sporadic inclusion body myositis: A double-blind, placebo-controlled study. J Neurol 247:22–28, 2000PubMed
57.
Dalakas MC: Sporadic inclusion body myositis-diagnosis, pathogenesis and therapeutic strategies. Nat Clin Pract Neurol 2:437–447, 2006PubMed
58.
Jayne DR, Davies MJ, Fox CJ, Black CM, Lockwood CM: Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet 337:1137–1139, 1991PubMed
59.
Jayne DR, Chapel H, Adu D, Misbah S, O’Donoghue D, Scott D, Lockwood CM: Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM 93:433–439, 2000PubMed
60.
Aries PM, Hellmich B, Gross WL: Intravenous immunoglobulin therapy in vasculitis: Speculation or evidence? Clin Rev Allergy Immunol 29:237–245, 2005PubMed
61.
Jayne DR, Lockwood CM: Intravenous immunoglobulin as sole therapy for systemic vasculitis. Br J Rheumatol 35:1150–1153, 1996PubMed
62.
Odum J, D’Costa D, Freeth M, Taylor D, Smith N, MacWhannell A: Cryoglobulinaemic vasculitis caused by intravenous immunoglobulin treatment. Nephrol Dial Transplant 16:403–406, 2001PubMed
63.
Levy Y, Sherer Y, Ahmed A, Langevitz P, George J, Fabbrizzi F, Terryberry J, Meissner M, Lorber M, Peter JB, Shoenfeld Y: A study of 20 SLE patients with intravenous immunoglobulin-clinical and serologic response. Lupus 8:705–712, 1999PubMed
64.
Boletis JN, Ioannidis JP, Boki KA, Moutsopoulos HM: Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis. Lancet 354:569–570, 1999PubMed
65.
Sherer Y, Levy Y, Shoenfeld Y: Intravenous immunoglobulin therapy of antiphospholipid syndrome. Rheumatology (Oxford) 39:421–426, 2000
66.
Bucciarelli S, Cervera R, Espinosa G, Gomez-Puerta JA, Ramos-Casals M, Font J: Mortality in the catastrophic antiphospholipid syndrome: Causes of death and prognostic factors. Autoimmun Rev 6:72–75, 2006PubMed
67.
Giannini EH, Lovell DJ, Silverman ED, Sundel RP, Tague BL, Ruperto N: Intravenous immunoglobulin in the treatment of polyarticular juvenile rheumatoid arthritis: A phase I/II study. Pediatric Rheumatology Collaborative Study Group. J Rheumatol 23:919–924, 1996PubMed
68.
Takahashi Y, Takata T, Hoshino M, Sakurai M, Kanazawa I: Benefit of IVIG for long-standing ataxic sensory neuronopathy with Sjogren’s syndrome. IV immunoglobulin. Neurology 60:503–505, 2003PubMed
69.
Sherer Y, Shoenfeld Y: Mechanisms of disease: atherosclerosis in autoimmune diseases. Nat Clin Pract Rheumatol 2:99–106, 2006PubMed
70.
Nicoletti A, Kaveri SV, Caligiuri G, Bariety J, Hansson G: Immunoglobulin treatment reduces atherosclerosis in apoE knockout mice. J Clin Invest 102:910–918, 1998PubMed
71.
Campione E, Marulli GC, Carrozzo AM, Chimenti MS, Costanzo A, Bianchi L: High-dose intravenous immunoglobulin for severe drug reactions: Efficacy in toxic epidermal necrolysis. Acta Derm Venereol 83:430–432, 2003PubMed
72.
Prins C, Kerdel FA, Padilla RS, Hunziker T, Chimenti S, Viard I, Mauri DN, Flynn K, Trent J, Margolis DJ, Saurat JH, French LE: Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: Multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol 139:26–32, 2003PubMed
73.
Jolles S: High-dose intravenous immunoglobulin (hdIVIg) in the treatment of autoimmune blistering disorders. Clin Exp Immunol 129:385–389, 2002PubMed
74.
Letko E, Miserocchi E, Daoud YJ, Christen W, Foster CS, Ahmed AR: A nonrandomized comparison of the clinical outcome of ocular involvement in patients with mucous membrane (cicatricial) pemphigoid between conventional immunosuppressive and intravenous immunoglobulin therapies. Clin Immunol 111:303–310, 2004PubMed
75.
Mimouni D, Blank M, Ashkenazi L, Milner Y, Frusic-Zlotkin M, Anhalt GJ, David M, Shoenfeld Y: Protective effect of intravenous immunoglobulin (IVIg) in an experimental model of pemphigus vulgaris. Clin Exp Immunol 142:426–432, 2005PubMed
76.
Jolles S, Sewell C, Webster D, Ryan A, Heelan B, Waite A, Rustin M: Adjunctive high-dose intravenous immunoglobulin treatment for resistant atopic dermatitis: Efficacy and effects on intracellular cytokine levels and CD4 counts. Acta Derm Venereol 83:433–437, 2003PubMed
77.
O’Donnell BF, Barr RM, Black AK, Francis DM, Kermani F, Niimi N, Barlow RJ, Winkelmann RK, Greaves MW: Intravenous immunoglobulin in autoimmune chronic urticaria. Br J Dermatol 138:101–106, 1998PubMed
78.
Karim A, Lawlor F, Black MM: Successful treatment of scleromyxoedema with high dose intravenous immunoglobulin. Clin Exp Dermatol 29:317–318, 2004PubMed
79.
Hagman JH, Carrozzo AM, Campione E, Romanelli P, Chimenti S: The use of high-dose immunoglobulin in the treatment of pyoderma gangrenosum. J Dermatolog Treat 12:19–22, 2001PubMed
80.
Gurmin V, Mediwake R, Fernando M, Whittaker S, Rustin MH, Beynon HL: Psoriasis: Response to high-dose intravenous immunoglobulin in three patients. Br J Dermatol 147:554–557, 2002PubMed
81.
Winston DJ, Antin JH, Wolff SN, Bierer BE, Small T, Miller KB, Linker C, Kaizer H, Lazarus HM, Petersen FB, Cowan MJ, Ho WG, Wingard JR, Schiller GJ, Territo MC, Jiao J, Petrarca MA, Tonetta SA: A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation. Bone Marrow Transplant 28:187–196, 2001PubMed
82.
Winston DJ, Ho WG, Bartoni K, Du Mond C, Ebeling DF, Buhles WC, Champlin RE: Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial. Ann Intern Med 118:179–184, 1993PubMed
83.
Sullivan KM, Storek J, Kopecky KJ, Jocom J, Longton G, Flowers M, Siadak M, Nims J, Witherspoon RP, Anasetti C, Appelbaum FR, Bowden RA, Buckner CD, Crawford SW, Deeg HJ, Hansen JA, McDonald GB, Sanders JE, Storb R: A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs.-host disease after marrow transplantation: Clinical outcome and effect on subsequent immune recovery. Biol Blood Marrow Transplant 2:44–53, 1996PubMed
84.
Glotz D, Antoine C, Julia P, Pegaz-Fiornet B, Duboust A, Boudjeltia S, Fraoui R, Combes M, Bariety J: Intravenous immunoglobulins and transplantation for patients with anti-HLA antibodies. Transpl Int 17:1–8, 2004PubMed
85.
Tyan DB, Li VA, Czer L, Trento A, Jordan SC: Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ. Transplantation 57:553–562, 1994PubMed
86.
Jordan SC, Quartel AW, Czer LS, Admon D, Chen G, Fishbein MC, Schwieger J, Steiner RW, Davis C, Tyan DB: Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Transplantation 66:800–805, 1998PubMed
87.
Magee JC, Collins BH, Harland RC, Lindman BJ, Bollinger RR, Frank MM, Platt JL: Immunoglobulin prevents complement-mediated hyperacute rejection in swine-to-primate xenotransplantation. J Clin Invest 96:2404–2412, 1995PubMedCrossRef
88.
Lutz HU, Stammler P, Bianchi V, Trueb RM, Hunziker T, Burger R, Jelezarova E, Spath PJ: Intravenously applied IgG stimulates complement attenuation in a complement-dependent autoimmune disease at the amplifying C3 convertase level. Blood 103:465–472, 2004PubMed
89.
Jordan SC, Tyan D, Stablein D, McIntosh M, Rose S, Vo A, Toyoda M, Davis C, Shapiro R, Adey D, Milliner D, Graff R, Steiner R, Ciancio G, Sahney S, Light J: Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: Report of the NIH IG02 trial. J Am Soc Nephrol 15:3256–3262, 2004PubMed
90.
Kaul R, McGeer A, Norrby-Teglund A, Kotb M, Schwartz B, O’Rourke K, Talbot J, Low DE: Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome—A comparative observational study. The Canadian Streptococcal Study Group. Clin Infect Dis 28:800–807, 1999PubMed
91.
Norrby-Teglund A, Kaul R, Low DE, McGeer A, Newton DW, Andersson J, Andersson U, Kotb M: Plasma from patients with severe invasive group A streptococcal infections treated with normal polyspecific IgG inhibits streptococcal superantigen-induced T cell proliferation and cytokine production. J Immunol 156:3057–3064, 1996PubMed
92.
Sriskandan S, Ferguson M, Elliot V, Faulkner L, Cohen J: Human intravenous immunoglobulin for experimental streptococcal toxic shock: Bacterial clearance and modulation of inflammation. J Antimicrob Chemother 58:117–124, 2006PubMed
93.
El-Nawawy A, El-Kinany H, Hamdy El-Sayed M, Boshra N: Intravenous polyclonal immunoglobulin administration to sepsis syndrome patients: A prospective study in a pediatric intensive care unit. J Trop Pediatr 51:271–278, 2005PubMed
94.
Gisslen M, Fredman P, Fuchs D, Lekman A, Rosengren L: Temporarily controlled HIV-1 replication after intravenous immunoglobulin treatment of Guillain–Barre syndrome. Scand J Infect Dis 37:877–881, 2005PubMed
95.
Lam L, Whitsett CF, McNicholl JM, Hodge TW, Hooper J: Immunologically active proteins in intravenous immunoglobulin. Lancet 342:678, 1993PubMed
96.
Blasczyk R, Westhoff U, Grosse-Wilde H: Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparations. Lancet 341:789–790, 1993PubMed
97.
Bayry J, Lacroix-Desmazes S, Delignat S, Mouthon L, Weill B, Kazatchkine MD, Kaveri SV: Intravenous immunoglobulin abrogates dendritic cell differentiation induced by interferon-alpha present in serum from patients with systemic lupus erythematosus. Arthritis Rheum 48:3497–3502, 2003PubMed
98.
Ryan ME, Webster ML, Statler JD: Adverse effects of intravenous immunoglobulin therapy. Clin Pediatr (Phila) 35:23–31, 1996CrossRef
99.
Jarius S, Eichhorn P, Albert MH, Wagenpfeil S, Wick M, Belohradsky BH, Hohlfeld R, Jenne DE, Voltz R: Intravenous immunoglobulins contain naturally occurring antibodies that mimic anti-neutrophil cytoplasmic antibodies and activate neutrophils in a TNF-alpha dependent and Fc-receptor independent way. Blood, 2007 (Epub ahead of Print)
100.
Gras V, Andrejak M, Decocq G: Acute renal failure associated with intravenous immunoglobulins. Pharmacoepidemiol Drug Saf 8(Suppl 1):S73–S78, 1999PubMed
101.
Katz U, Shoenfeld Y: Review: intravenous immunoglobulin therapy and thromboembolic complications. Lupus 14:802–808, 2005PubMed
102.
Chapel HM: Safety and availability of immunoglobulin replacement therapy in relation to potentially transmissable agents. IUIS Committee on Primary Immunodeficiency Disease. International Union of Immunological Societies. Clin Exp Immunol 118(Suppl 1):29–34, 1999PubMed
103.
Gregori L, Maring JA, MacAuley C, Dunston B, Rentsch M, Kempf C, Rohwer RG: Partitioning of TSE infectivity during ethanol fractionation of human plasma. Biologicals 32:1–10, 2004PubMed
104.
Sewell WA, Jolles S: Immunomodulatory action of intravenous immunoglobulin. Immunology 107:387–393, 2002PubMed
105.
Nimmerjahn F, Ravetch JV: Fcgamma receptors: old friends and new family members. Immunity 24:19–28, 2006PubMed
106.
Binstadt BA, Geha RS, Bonilla FA: IgG Fc receptor polymorphisms in human disease: Implications for intravenous immunoglobulin therapy. J Allergy Clin Immunol 111:697–703, 2003PubMed
107.
Debre M, Bonnet MC, Fridman WH, Carosella E, Philippe N, Reinert P, Vilmer E, Kaplan C, Teillaud JL, Griscelli C: Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet 342:945–949, 1993PubMed
108.
Akilesh S, Petkova S, Sproule TJ, Shaffer DJ, Christianson GJ, Roopenian D: The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease. J Clin Invest 113:1328–1333, 2004PubMed
109.
Li N, Zhao M, Hilario-Vargas J, Prisayanh P, Warren S, Diaz LA, Roopenian DC, Liu Z: Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases. J Clin Invest 115:3440–3450, 2005PubMed
110.
Samuelsson A, Towers TL, Ravetch JV: Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291:484–486, 2001PubMed
111.
Kaneko Y, Nimmerjahn F, Madaio MP, Ravetch JV: Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors. J Exp Med 203:789–797, 2006PubMed
112.
Nimmerjahn F, Ravetch JV: The antiinflammatory activity of IgG: the intravenous IgG paradox. J Exp Med 204:11–15, 2007PubMed
113.
Siragam V, Crow AR, Brinc D, Song S, Freedman J, Lazarus AH: Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells. Nat Med 12:688–692, 2006PubMed
114.
Park-Min KH, Serbina NV, Yang W, Ma X, Krystal G, Neel BG, Nutt SL, Hu X, Ivashkiv LB: FcgammaRIII-dependent inhibition of interferon-gamma responses mediates suppressive effects of intravenous immune globulin. Immunity 26:67–78, 2007PubMed
115.
Kaneko Y, Nimmerjahn F, Ravetch JV: Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313:670–673, 2006PubMed
116.
Bayry J, Kazatchkine MD, Kaveri SV: Shortage of human intravenous immunoglobulin—reasons and possible solutions. Nat Clin Pract Neurol 3:119–120, 2007
117.
Kazatchkine MD, Dietrich G, Hurez V, Ronda N, Bellon B, Rossi F, Kaveri SV: V Region-mediated selection of autoreactive repertoires by intravenous immunoglobulin (IVIg). Immunol Rev 139:79–107, 1994PubMed
118.
Sami N, Bhol KC, Ahmed AR: Influence of IVIg therapy on autoantibody titers to desmoglein 1 in patients with pemphigus foliaceus. Clin Immunol 105:192–198, 2002PubMed
119.
Sami N, Bhol KC, Ahmed RA: Influence of intravenous immunoglobulin therapy on autoantibody titers to desmoglein 3 and desmoglein 1 in pemphigus vulgaris. Eur J Dermatol 13:377–381, 2003PubMed
120.
Dalakas MC: Intravenous immune globulin therapy for neurologic diseases. Ann Intern Med 126:721–730, 1997PubMed
121.
Liblau R, Gajdos P, Bustarret FA, el Habib R, Bach JF, Morel E: Intravenous gamma-globulin in myasthenia gravis: Interaction with anti-acetylcholine receptor autoantibodies. J Clin Immunol 11:128–131, 1991PubMed
122.
Basta M, Fries LF, Frank MM: High-dose intravenous immunoglobulin inhibits in vitro uptake of C4 fragments onto sensitized erythrocytes. Blood 77:376–380, 1991PubMed
123.
Vuist WM, van Schaik IN, van Lint M, Brand A: The growth arresting effect of human immunoglobulin for intravenous use is mediated by antibodies recognizing membrane glycolipids. J Clin Immunol 17:301–310, 1997PubMed
124.
Mollnes TE, Hogasen K, De Carolis C, Vaquero E, Nielsen EW, Fontana L, Perricone R: High-dose intravenous immunoglobulin treatment activates complement in vivo. Scand J Immunol 48:312–317, 1998PubMed
125.
Basta M, van Goor F, Luccioli S, Billings EM, Vortmeyer AO, Baranyi L, Szebeni J, Alving CR, Carroll MC, Berkower I, Stojilkovic SS, Metcalfe DD: F(ab′)2-mediated neutralization of C3a and C5a anaphylatoxins: A novel effector function of immunoglobulins. Nat Med 9:431–438, 2003PubMed
126.
Andersson U, Bjork L, Skansen SU, Andersson J: Pooled human IgG modulates cytokine production in lymphocytes and monocytes. Immunol Rev 139:21–42, 1994PubMed
127.
Bhol KC, Desai A, Kumari S, Colon JE, Ahmed AR: Pemphigus vulgaris: The role of IL-1 and IL-1 receptor antagonist in pathogenesis and effects of intravenous immunoglobulin on their production. Clin Immunol 100:172–180, 2001PubMed
128.
Andersson UG, Bjork L, Skansen-Saphir U, Andersson JP: Down-regulation of cytokine production and interleukin-2 receptor expression by pooled human IgG. Immunology 79:211–216, 1993PubMed
129.
Ruiz de Souza V, Carreno MP, Kaveri SV, Ledur A, Sadeghi H, Cavaillon JM, Kazatchkine MD, Haeffner-Cavaillon N: Selective induction of interleukin-1 receptor antagonist and interleukin-8 in human monocytes by normal polyspecific IgG (intravenous immunoglobulin). Eur J Immunol 25:1267–1273, 1995PubMed
130.
Sharief M, Ingram D, Swash M, Thompson E: I.v. immunoglobulin reduces circulating proinflammatory cytokines in Guillain–Barre syndrome. Neurology 52:1833–1838, 1999PubMed
131.
Mouzaki A, Theodoropoulou M, Gianakopoulos I, Vlaha V, Kyrtsonis MC, Maniatis A: Expression patterns of Th1 and Th2 cytokine genes in childhood idiopathic thrombocytopenic purpura (ITP) at presentation and their modulation by intravenous immunoglobulin G (IVIg) treatment: Their role in prognosis. Blood 100:1774–1779, 2002PubMed
132.
Bouhlal H, Hocini H, Quillent-Gregoire C, Donkova V, Rose S, Amara A, Longhi R, Haeffner-Cavaillon N, Beretta A, Kaveri SV, Kazatchkine MD: Antibodies to C-C chemokine receptor 5 in normal human IgG block infection of macrophages and lymphocytes with primary R5-tropic strains of HIV-1. J Immunol 166:7606–7611, 2001PubMed
133.
Bayry J, Lacroix-Desmazes S, Donkova-Petrini V, Carbonneil C, Misra N, Lepelletier Y, Delignat S, Varambally S, Oksenhendler E, Levy Y, Debre M, Kazatchkine MD, Hermine O, Kaveri SV: Natural antibodies sustain differentiation and maturation of human dendritic cells. Proc Natl Acad Sci USA 101:14210–14215, 2004PubMed
134.
Banchereau J, Schuler-Thurner B, Palucka AK, Schuler G: Dendritic cells as vectors for therapy. Cell 106:271–274, 2001PubMed
135.
Bayry J, Lacroix-Desmazes S, Carbonneil C, Misra N, Donkova V, Pashov A, Chevailler A, Mouthon L, Weill B, Bruneval P, Kazatchkine MD, Kaveri SV: Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood 101:758–765, 2003PubMed
136.
Bayry J, Lacroix-Desmazes S, Kazatchkine MD, Galicier L, Lepelletier Y, Webster D, Levy Y, Eibl MM, Oksenhendler E, Hermine O, Kaveri SV: Common variable immunodeficiency is associated with defective functions of dendritic cells. Blood 104:2441–2443, 2004PubMed
137.
Bayry J, Lacroix-Desmazes S, Hermine O, Oksenhendler E, Kazatchkine MD, Kaveri SV: Amelioration of differentiation of dendritic cells from CVID patients by intravenous immunoglobulin. Am J Med 118:1439–1440, 2005PubMed
138.
Bayry J, Hermine O, Webster DA, Levy Y, Kaveri SV: Common variable immunodeficiency: The immune system in chaos. Trends Mol Med 11:370–376, 2005PubMed
139.
Rodriguez M, Miller DJ, Lennon VA: Immunoglobulins reactive with myelin basic protein promote CNS remyelination. Neurology 46:538–545, 1996PubMed
140.
van Engelen BG, Miller DJ, Pavelko KD, Hommes OR, Rodriguez M: Promotion of remyelination by polyclonal immunoglobulin in Theiler’s virus-induced demyelination and in multiple sclerosis. J Neurol Neurosurg Psychiatry 57(Suppl):65–68, 1994PubMedCrossRef
141.
Gabriel CM, Gregson NA, Redford EJ, Davies M, Smith KJ, Hughes RA: Human immunoglobulin ameliorates rat experimental autoimmune neuritis. Brain 120(Pt 9):1533–1540, 1997PubMed
142.
Kuhlmann T, Bruck W: Immunoglobulins induce increased myelin debris clearance by mouse macrophages. Neurosci Lett 275:191–194, 1999PubMed
143.
Bonner JC, Osornio-Vargas AR, Badgett A, Brody AR: Differential proliferation of rat lung fibroblasts induced by the platelet-derived growth factor-AA, -AB, and -BB isoforms secreted by rat alveolar macrophages. Am J Respir Cell Mol Biol 5:539–547, 1991PubMed
Metadata
Title
Intravenous Immunoglobulin: An Update on the Clinical Use and Mechanisms of Action
Authors
VIR-SINGH NEGI
SRIRAMULU ELLURU
SOPHIE SIBÉRIL
STÉPHANIE GRAFF-DUBOIS
LUC MOUTHON
MICHEL D. KAZATCHKINE
SÉBASTIEN LACROIX-DESMAZES
JAGADEESH BAYRY
SRINI V. KAVERI
Publication date
01-05-2007
Published in
Journal of Clinical Immunology / Issue 3/2007
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-007-9088-9

Other articles of this Issue 3/2007

Journal of Clinical Immunology 3/2007 Go to the issue

Original Paper

Long-Term Follow-Up and Outcome of a Large Cohort of Patients with Common Variable Immunodeficiency

OriginalPaper

Clinical and Laboratory Findings in Iranian Patients with Leukocyte Adhesion Deficiency (Study of 15 Cases)

Original Article

BAFF, a New Target for Intravenous Immunoglobulin in Autoimmunity and Cancer

Original Paper

CD4 +CD25 + Regulatory T Cells Decreased the Antitumor Activity of Cytokine-Induced Killer (CIK) Cells of Lung Cancer Patients

OriginalPaper

Stability of Protease-Rich Periplaneta americana Allergen Extract During Storage: Formulating Preservatives to Enhance Shelf Life

OriginalPaper

Unexpected Immunoresponse to Gal and APA Antigens in Diabetic Type 1 Patients Receiving Neonatal Pig Islets After 6 Years
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits